Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.

To better understand the biology of hormone receptor-positive and-negative breast cancer and to identify methylated gene markers of disease progression, we carried out a genome-wide methylation array analysis on 103 primary invasive breast cancers and 21 normal breast samples, using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Estrogen and/or progesterone receptor-positive tumors displayed more hypermethylated loci than estrogen receptor (ER)-negative tumors. However, the hypermethylated loci in ER-negative tumors were clustered closer to the transcriptional start site compared with ER-positive tumors. An ER-classifier set of CpG loci was identified, which independently partitioned primary tumors into ER subtypes. A total of 40 (32 novel and 8 previously known) CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER subtype-specific loci was validated in silico, using an independent, publicly available methylome dataset from the Cancer Genome Atlas. In addition, we identified 100 methylated CpG loci that were significantly associated with disease progression; the majority of these loci were informative particularly in ER-negative breast cancer. Overall, the set was highly enriched in homeobox containing genes. This pilot study shows the robustness of the breast cancer methylome and illustrates its potential to stratify and reveal biological differences between ER subtypes of breast cancer. Furthermore, it defines candidate ER-specific markers and identifies potential markers predictive of outcome within ER subgroups.

[1]  S. Sukumar,et al.  Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer , 2001, Oncogene.

[2]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[3]  Saraswati Sukumar,et al.  The Hox genes and their roles in oncogenesis , 2010, Nature Reviews Cancer.

[4]  Patrick Pauwels,et al.  Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination , 2010, PloS one.

[5]  R. Eeles,et al.  Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls , 2007, Breast Cancer Research.

[6]  M. Fackler,et al.  DNA methylation of RASSF1A, HIN‐1, RAR‐β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma , 2003, International journal of cancer.

[7]  Soonmyung Paik,et al.  Gene-expression-based prognostic assays for breast cancer , 2010, Nature Reviews Clinical Oncology.

[8]  M. Salto‐Tellez,et al.  RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. , 2006, Cancer research.

[9]  Fang Fang,et al.  Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis , 2011, Science Translational Medicine.

[10]  Sherif Abou Elela,et al.  Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes , 2008, Molecular Cancer Therapeutics.

[11]  D. Wickerham,et al.  Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. , 2001, Journal of the National Cancer Institute. Monographs.

[12]  Krystyna Kiel,et al.  Breast cancer. Clinical practice guidelines in oncology. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  M. Fackler,et al.  Two-color quantitative multiplex methylation-specific PCR. , 2006, BioTechniques.

[14]  M. Fackler,et al.  Hypermethylated Genes as Biomarkers of Cancer in Women with Pathologic Nipple Discharge , 2009, Clinical Cancer Research.

[15]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[16]  F. Bertucci,et al.  Gene expression profiling of breast cell lines identifies potential new basal markers , 2006, Oncogene.

[17]  Martin Widschwendter,et al.  Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. , 2006, Cancer research.

[18]  S. Sukumar,et al.  Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. , 2001, Oncogene.

[19]  J. Pollack,et al.  LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. , 2010, Cancer research.

[20]  F. Muggia,et al.  Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. , 2001, Journal of the National Cancer Institute.

[21]  S. Paik,et al.  Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. , 2009, Breast.

[22]  Wonshik Han,et al.  Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. , 2010, Human molecular genetics.

[23]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[24]  N. Wolmark,et al.  Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. , 2001, Journal of the National Cancer Institute.

[25]  Wei Huang,et al.  Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer. , 2010, Human pathology.

[26]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Johan Staaf,et al.  Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns , 2010, Breast Cancer Research.

[28]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[29]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[30]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Zhe Zhang,et al.  Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis , 2008, Cancer biology & therapy.

[32]  Pedram Argani,et al.  Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer , 2004, Cancer Research.

[33]  G. Parmigiani,et al.  Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers , 2008, Proceedings of the National Academy of Sciences.

[34]  Vinay Varadan,et al.  DNA methylation patterns in luminal breast cancers differ from non‐luminal subtypes and can identify relapse risk independent of other clinical variables , 2011, Molecular oncology.

[35]  S Badve,et al.  Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22 , 2011, Oncogene.

[36]  Zhe Zhang,et al.  Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid , 2006, Clinical Cancer Research.

[37]  T. Aas,et al.  DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response , 2010, Molecular Cancer.

[38]  Renee F Wilson,et al.  Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer , 2008, Annals of Internal Medicine.

[39]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[40]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[41]  G. Sauter,et al.  Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer. , 2010, Human pathology.

[42]  C. Ricketts,et al.  Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. , 2011, Cancer research.

[43]  E. van Marck,et al.  Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients , 2010, BMC Cancer.

[44]  R. Simon,et al.  Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling. , 2006, Journal of the National Cancer Institute.

[45]  L. V. van't Veer,et al.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.

[46]  U. Lehmann,et al.  Quantitative assessment of promoter hypermethylation during breast cancer development. , 2002, The American journal of pathology.